Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: Comparison between T790M mutation‐positive and mutation‐negative populations

Hata, Akito; Katakami, Nobuyuki; Yoshioka, Hiroshige; Takeshita, Jumpei; Tanaka, Kosuke; Nanjo, Shigeki; Fujita, Shiro; Kaji, Reiko; Imai, Yukihiro; Monden, Kazuya; Matsumoto, Takeshi; Nagata, Kazuma; Otsuka, Kyoko; Tachikawa, Ryo; Tomii, Keisuke; Kunimasa, Kei; Iwasaku, Masahiro; Nishiyama, Akihiro; Ishida, Tadashi; Nishimura, Yoshihiro

doi:10.1002/cncr.28364

Cited by 179Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchLung Cancer Diagnosis and Treatment

Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: Comparison between T790M mutation‐positive and mutation‐negative populations

Hata, Akito, Katakami, Nobuyuki, Yoshioka, Hiroshige, Takeshita, Jumpei, Tanaka, Kosuke, Nanjo, Shigeki, Fujita, Shiro, Kaji, Reiko +12 more·2013·Cancer

DOI 10.1002/cncr.28364

Open this paper in CoChat — free account

Abstract

BACKGROUND: The secondary epidermal growth factor receptor (EGFR) mutation Thr790Met (T790M) accounts for approximately half of acquired resistances to EGFR-tyrosine kinase inhibitor (TKI). Recent reports have demonstrated that the emergence of T790M predicts a favorable prognosis and indolent progression. However, rebiopsy to confirm T790M status can be challenging due to limited tissue availability and procedural feasibility, and little is known regarding the differences among patients with or without T790M mutation. METHODS: The study investigated 78 EGFR-mutant patients who had undergone rebiopsy after TKI failure. The peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp method was used in EGFR mutational analyses. Various patient characteristics and postprogression survivals (PPSs) after initial TKI failure were retrospectively compared in patients with and without T790M. RESULTS: The T790M mutation was identified in 4 (17%) of 24 central nervous system lesions, and in 22 (41%) of 54 other lesions (P = .0417). No other characteristics had a statistical association with T790M prevalence. Median PPS was 31.4 months in 26 patients with T790M, and 11.4 months in 52 patients without T790M (P = .0017). In the multivariate analysis, statistically significant factors for longer PPS included T790M-positive, good performance status, and no carcinomatous meningitis. CONCLUSIONS: The emergence of T790M in central nervous system lesions was rare, compared with other lesions. Patients with T790M after TKI failure appear to have better prognoses than those without T790M. TKI rechallenge or continuous administration beyond progression may be effective after initial TKI failure.

Integrity signals

Registry

Crossref · 10.1002/cncr.28364

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The EGFR T790M somatic mutation is the most frequent alteration found in about half of tumors that progress on first- or second-generation EGFR TKIs.
“with the EGFR T790M somatic mutation being the most frequent alteration detected in approximately half of progressing tumors.[14][15][16]”
From The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016 (2016) · cites this paper as [15]

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · see citing works
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525 · see citing works
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · see citing works
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · see citing works
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090 · see citing works
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081 · see citing works
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964 · see citing works
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · see citing works
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499 · see citing works
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454 · see citing works
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Jackman, D., Pao, W., Riely, G. J., Engelman, J. A., Kris, M. G., Jänne, P. A., Lynch, T., Johnson, B. E., & Miller, V. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.7049 · Cited by 793 · see citing works
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer
Weickhardt, A. J., Scheier, B., Burke, J. M., Gan, G., Lu, X., Bunn, P. A., Aisner, D. L., Gaspar, L. E., Kavanagh, B. D., Doebele, R. C., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182745948 · Cited by 684 · see citing works
Primary Retroperitoneal Sarcomas: A Multivariate Analysis of Surgical Factors Associated With Local Control
Bonvalot, S., Rivoire, M. L., Castaing, M., Stoeckle, E., Cesne, A. L., Blay, J., & Laplanche, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0802 · Cited by 644 · see citing works
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations
Yano, S., Wang, W., Li, Q., Matsumoto, K., Sakurama, H., Nakamura, T., Ogino, H., Kakiuchi, S., Hanibuchi, M., Nishioka, Y., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1643 · Cited by 643 · see citing works
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
Oxnard, G. R., Arcila, M. E., Sima, C. S., Riely, G. J., Chmielecki, J., Kris, M. G., Pao, W., Ladanyi, M., & Miller, V. A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2692 · Cited by 627 · see citing works
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
Arcila, M. E., Oxnard, G. R., Nafa, K., Riely, G. J., Solomon, S. B., Zakowski, M. F., Kris, M. G., Pao, W., Miller, V. A., & Ladanyi, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2277 · Cited by 574 · see citing works
Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling
Chmielecki, J., Foo, J., Oxnard, G. R., Hutchinson, K. E., Ohashi, K., Somwar, R., Wang, L., Amato, K. R., Arcila, M. E., Sos, M. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002356 · Cited by 519 · see citing works
Genetic Heterogeneity of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cell Lines Revealed by a Rapid and Sensitive Detection System, the Peptide Nucleic Acid-Locked Nucleic Acid PCR Clamp
Nagai, Y., Miyazawa, H., Huqun, Tanaka, T., Udagawa, K., Kato, M., Fukuyama, S., Yokote, A., Kobayashi, K., Kanazawa, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0331 · Cited by 503 · see citing works
New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer
Oxnard, G. R., Arcila, M. E., Chmielecki, J., Ladanyi, M., Miller, V. A., & Pao, W. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2571 · Cited by 355 · see citing works
“Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
Grommes, C., Oxnard, G. R., Kris, M. G., Miller, V. A., Pao, W., Holodny, A. I., Clarke, J. L., & Lassman, A. B. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor121 · Cited by 349 · see citing works
Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
Yu, H. A., Sima, C. S., Huang, J. G., Solomon, S. B., Rimner, A., Paik, P. K., Pietanza, M. C., Azzoli, C. G., Rizvi, N. A., Krug, L. M., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827e1f83 · Cited by 340 · see citing works
Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Wang, W., Li, Q., Yamada, T., Matsumoto, K., Matsumoto, I., Oda, M., Watanabe, G., Kayano, Y., Nishioka, Y., Sone, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1001 · Cited by 297 · see citing works
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib
Jackman, D. M., Holmes, A. J., Lindeman, N., Wen, P. Y., Kesari, S., Borras, A. M., Bailey, C., de Jong, F., Jänne, P. A., & Johnson, B. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6126 · Cited by 260 · see citing works
High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer
Clarke, J. L., Pao, W., Wu, N., Miller, V. A., & Lassman, A. B. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0128-6 · Cited by 214 · see citing works
Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib
Katayama, T., Shimizu, J., Suda, K., Onozato, R., Fukui, T., Ito, S., Hatooka, S., Sueda, T., Hida, T., Yatabe, Y., et al. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181b62572 · Cited by 161 · see citing works
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations
Nishie, K., Kawaguchi, T., Tamiya, A., Mimori, T., Takeuchi, N., Matsuda, Y., Omachi, N., Asami, K., Okishio, K., Atagi, S., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31826913f7 · Cited by 104 · see citing works
Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selection
Hata, A., Katakami, N., Yoshioka, H., Fujita, S., Kunimasa, K., Nanjo, S., Otsuka, K., Kaji, R., Tomii, K., Iwasaku, M., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.03.010 · Cited by 65 · see citing works
Carcinomatous Meningitis in Non–Small-Cell Lung Cancer: Response to High-Dose Erlotinib
Dhruva, N., & Socinski, M. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0963 · Cited by 64 · see citing works
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer
Kaira, K., Naito, T., Takahashi, T., Ayabe, E., Shimoyama, R., Kaira, R., Ono, A., Igawa, S., Shukuya, T., Murakami, H., et al. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.05.006 · Cited by 61 · see citing works
High-dose Erlotinib for Refractory Brain Metastases in a Patient with Relapsed Non-small Cell Lung Cancer
Hata, A., Kaji, R., Fujita, S., & Katakami, N. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d899bb · Cited by 50 · see citing works
Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib
Asahina, H., Oizumi, S., Inoue, A., Kinoshita, I., Ishida, T., Fujita, Y., Sukoh, N., Harada, M., Maemondo, M., Saijo, Y., et al. (2010) · Oncology · doi:10.1159/000326488 · Cited by 47 · see citing works
Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR-mutant lung cancer.
Oxnard, G. R., Lo, P. C., Jackman, D. M., Butaney, M., Héon, S., Johnson, B. E., Sequist, L. V. D., & Janne, P. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.7547 · Cited by 34 · see citing works
Does T790M Disappear? Successful Gefitinib Rechallenge After T790M Disappearance in a Patient With EGFR-Mutant Non–Small-Cell Lung Cancer
Hata, A., Katakami, N., Kaji, R., Fujita, S., & Imai, Y. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318282e047 · Cited by 19 · see citing works
T790M is associated with a favorable prognosis in Japanese patients treated with an EGFR-TKI
Uramoto, H., Yano, S., & Tanaka, F. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.01.010 · Cited by 19 · see citing works
Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in EGFR-mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance.
Héon, S., Nishino, M., Goldberg, S. B., Porter, J., Sequist, L. V. D., Jackman, D. M., & Johnson, B. E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.7525 · Cited by 14 · see citing works

Flagged first, then by citations

Sorted by citations

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454 · see citing works
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E., Colasacco, C., Đačić, S., Hirsch, F. R., Kerr, K. M., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0388-cp · Cited by 959 · see citing works
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Reungwetwattana, T., Nakagawa, K., Cho, B. C., Cobo, M., Cho, E. K., Bertolini, A., Bohnet, S., Zhou, C., Lee, K. H., Nogami, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.3118 · Cited by 811 · see citing works
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors
Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E., Colasacco, C., Đačić, S., Hirsch, F. R., Kerr, K. M., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.12.001 · Cited by 660 · see citing works
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)
Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Han, J.-Y., Katakami, N., Kim, H. R., Hodge, R., Kaur, P., Brown, A. P., Ghiorghiu, D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9363 · Cited by 517 · see citing works
Self-citation
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
Ohashi, K., Maruvka, Y. E., Michor, F., & Pao, W. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3912 · Cited by 467 · see citing works
Advances in studies of tyrosine kinase inhibitors and their acquired resistance
Jiao, Q., Bi, L., Ren, Y., Song, S., Wang, Q., & Wang, Y. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0801-5 · Cited by 399 · see citing works
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors
Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E., Colasacco, C., Đačić, S., Hirsch, F. R., Kerr, K. M., et al. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.11.004 · Cited by 348 · see citing works
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
Li, Y.-S., Jiang, B., Yang, J., Tu, H., Zhou, Q. H., Guo, W., Yan, H., & Wu, Y.-L. L. C. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.029 · Cited by 313 · see citing works
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.
Stewart, E., Tan, S. Z., Liu, G., & Tsao, M. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.11.06 · Cited by 311 · see citing works
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials
Goss, G., Tsai, C.-M., Shepherd, F. A., Ahn, M.-J., Bazhenova, L., Crinò, L., de Marinis, F., Felip, E., Morabito, A., Hodge, R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx820 · Cited by 247 · see citing works
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
Wu, S.-G., Liu, Y.-N., Tsai, M.-F., Chang, Y.-L., Yu, C.-J., Yang, P.-C., Yang, J. C.-H., Wen, Y.-F., & Shih, J.-Y. (2016) · Oncotarget · doi:10.18632/oncotarget.7189 · Cited by 234 · see citing works
Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
Zheng, D., Ye, X.-R., Zhang, M. Z., Sun, Y., Wang, J. Y., Ni, J., Zhang, H. P., Zhang, L., Luo, J., Zhang, J., et al. (2016) · Scientific Reports · doi:10.1038/srep20913 · Cited by 224 · see citing works
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016
Tan, D. S. W., Yom, S. S., Tsao, M. S., Pass, H. I., Kelly, K., Peled, N., Yung, R. C., Wistuba, I. I., Yatabe, Y., Unger, M., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.008 · Cited by 201 · see citing works
EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.
Lin, Y., Wang, X., & Jin, H. (2014) · Europe PMC (PubMed Central) · Cited by 198 · see citing works
Lung Cancer in the Era of Precision Medicine
Politi, K. A., & Herbst, R. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2748 · Cited by 187 · see citing works
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
Liao, B.-C., Lee, J., Lin, C., Chen, Y., Chang, C., Ho, C., Shih, J., Yu, C., & Yang, J. C. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000669 · Cited by 183 · see citing works
Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non–Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI
Hata, A., Katakami, N., Yoshioka, H., Kaji, R., Masago, K., Fujita, S., Imai, Y., Nishiyama, A., Ishida, T., Nishimura, Y., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000647 · Cited by 150 · see citing works
Exploring receptor tyrosine kinases-inhibitors in Cancer treatments
Metibemu, D. S., Akinloye, O. A., Akamo, A. J., Ojo, D. A., Okeowo, T. O., & Omotuyi, O. I. (2019) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-019-0035-0 · Cited by 146 · see citing works
Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC
Wang, Z., Chen, R., Wang, S., Zhong, J., Wu, M., Zhao, J., Duan, J., Zhuo, M., An, T., Wang, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110780 · Cited by 129 · see citing works
Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells
Jiang, B., Li, Y.-S., Guo, W., Zhang, X., Chen, Z., Su, J., Zhong, W., Yang, X., Yang, J., Shao, Y. W., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0047 · Cited by 121 · see citing works
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going
Russo, A., Franchina, T., Ricciardi, G. R. R., Smiroldo, V., Picciotto, M., Zanghì, M., Rolfo, C. D., & Adamo, V. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.07.003 · Cited by 109 · see citing works
Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC—a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier: ChiCTR1800016615)
Fan, C., Zhao, Q., Li, L., Shen, W., Du, Y., Teng, C., Gao, F., Song, X., Jiang, Q., Huang, D., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.018 · Cited by 103 · see citing works
Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature
van der Wekken, A. J., Saber, A., Hiltermann, T. J. N., Kok, K., van den -->Berg, A., & Groen, H. J. M. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.01.024 · Cited by 98 · see citing works
AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases
Yang, Z., Guo, Q., Wang, Y., Chen, K., Zhang, L., Cheng, Z., Xu, Y., Yin, X., Bai, Y., Rabbie, S. C., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0976 · Cited by 98 · see citing works
Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
Matsuo, N., Azuma, K., Sakai, K., Hattori, S., Kawahara, A., Ishii, H., Tokito, T., Kinoshita, T., Yamada, K., Nishio, K., et al. (2016) · Scientific Reports · doi:10.1038/srep36458 · Cited by 96 · see citing works
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R
Ke, E., Zhou, Q. H., Zhang, Q.-Y., Su, J., Chen, Z., Zhang, X., Xu, C., Yang, J., Tu, H., Yan, H., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.05.018 · Cited by 95 · see citing works
T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients
Li, W., Ren, S., Li, J., Li, A., Fan, L., Li, X., Zhao, C., He, Y., Gao, G., Chen, X., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.03.011 · Cited by 95 · see citing works
A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR‐TKI resistance
Wang, W., Song, Z., & Zhang, Y. (2016) · Cancer Medicine · doi:10.1002/cam4.978 · Cited by 93 · see citing works
Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies
Koulouris, A., Tsagkaris, C., Corriero, A. C., Metro, G., & Mountzios, G. (2022) · Cancers · doi:10.3390/cancers14143337 · Cited by 99 · see citing works
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
Yang, C., Liao, W., Ho, C., Chen, K., Tsai, T.-H., Hsu, C., Su, K., Chang, Y., Wu, C., Hsu, C., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.10.019 · Cited by 90 · see citing works
Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure
Kawamura, T., Kenmotsu, H., Taira, T., Omori, S., Nakashima, K., Wakuda, K., Ono, A., Naito, T., Murakami, H., Mori, K. P., et al. (2016) · Cancer Science · doi:10.1111/cas.12963 · Cited by 87 · see citing works
Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression
Aldea, M. D., Hendriks, L. E. L., Mezquita, L., Jovelet, C., Planchard, D., Auclin, É., Remón, J., Howarth, K., Benítez, J. C., Gazzah, A., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.11.024 · Cited by 87 · see citing works
Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
Kelly, W., Shah, N. J., & Subramaniam, D. S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00208 · Cited by 86 · see citing works
The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.
Wu, F., Li, J., Jang, C., Wang, J., & Xiong, J. (2014) · PubMed Central · Cited by 85 · see citing works
Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis
Wang, Z.-F., Ren, S., Li, W., & Gao, G. (2018) · BMC Cancer · doi:10.1186/s12885-018-4075-5 · Cited by 86 · see citing works
Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment
Remón, J., & Besse, B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00088 · Cited by 79 · see citing works
Acquisition of cancer stem cell‐like properties in non‐small cell lung cancer with acquired resistance to afatinib
Hashida, S., Yamamoto, H., Shien, K., Miyoshi, Y., Ohtsuka, T., Suzawa, K., Watanabe, M., Maki, Y., Soh, J., Asano, H., et al. (2015) · Cancer Science · doi:10.1111/cas.12749 · Cited by 77 · see citing works
EGFR–Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors
Barnet, M. B., O'Toole, S. A., Horvath, L. G., Selinger, C. I., Yu, B., Ng, C. C., Boyer, M. J., Cooper, W. A., & Kao, S. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.001 · Cited by 77 · see citing works
Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors
Dorantes-Heredia, R., Ruiz-Morales, J. M., & Cano-García, F. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.07.10 · Cited by 71 · see citing works
Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?
Le, T., & Gerber, D. E. (2019) · Cancers · doi:10.3390/cancers11030366 · Cited by 73 · see citing works
Cell-Cycle and DNA-Damage Response Pathway Is Involved in Leptomeningeal Metastasis of Non–Small Cell Lung Cancer
Fan, Y., Zhu, X., Xu, Y., Lu, X., Xu, Y., Wang, M., Xu, H., Ding, J., Ye, X., Fang, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1582 · Cited by 67 · see citing works
Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study
Sueoka‐Aragane, N., Katakami, N., Satouchi, M., Yokota, S., Aoe, K., Iwanaga, K., Otsuka, K., Morita, S., Kimura, S. H., Negoro, S., et al. (2015) · Cancer Science · doi:10.1111/cas.12847 · Cited by 66 · see citing works
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
Liang, S., Hsieh, M., Lee, M., Keng, L., Ko, J., & Shih, J. (2017) · Oncotarget · doi:10.18632/oncotarget.19563 · Cited by 63 · see citing works
Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs
Lee, C., Kim, S., Lee, J. E., Lee, J. E., Kim, S.-M., Yang, I. S., Kim, H. R., Lee, J. H., Kim, S., & Cho, B. C. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.09.005 · Cited by 62 · see citing works
Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases
Huang, R., Xu, X. L., Li, D., Chen, K., Zhan, Q., Ge, M., Zhou, X., Liang, X., & Guan, M. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00645-5 · Cited by 62 · see citing works
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer
Ahluwalia, M. S., Becker, K. D., & Levy, B. P. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0572 · Cited by 59 · see citing works
Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients
Ko, R., Kenmotsu, H., Serizawa, M., Koh, Y., Wakuda, K., Ono, A., Taira, T., Naito, T., Murakami, H., Isaka, M., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2902-0 · Cited by 59 · see citing works
Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs
Liu, Y., Sun, L., Xiong, Z., Sun, X., Zhang, S., Ma, J., & Han, C. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s133082 · Cited by 54 · see citing works
Role of Rebiopsy in Relapsed Non-Small Cell Lung Cancer for Directing Oncology Treatments
Jekunen, A. P. (2015) · Journal of Oncology · doi:10.1155/2015/809835 · Cited by 53 · see citing works
Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure
Sasaki, S., Yoshioka, Y., Ko, R., Katsura, Y., Namba, Y., Shukuya, T., Kido, K., Iwakami, S., Tominaga, S., & Takahashi, K. (2015) · Respiratory Investigation · doi:10.1016/j.resinv.2015.07.001 · Cited by 53 · see citing works
Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance
Tartarone, A., & Lerose, R. (2015) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465815587820 · Cited by 53 · see citing works
EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases
Zhao, J., Ye, X., Xu, Y., Chen, M., Zhong, W., Sun, Y., Yang, Z., Zhu, G., Gu, Y., & Wang, M. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3155-y · Cited by 53 · see citing works
The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy: a literature-based pooled analysis
written on behalf of AME Lung Cancer Cooperative Group, Liang, H., Pan, Z., Wang, W., Guo, C., Chen, D., Zhang, J., Zhang, Y., Tang, S., He, J., et al. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.03.150 · Cited by 51 · see citing works
RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation
Yoshida, T., Yoh, K., Niho, S., Umemura, S., Matsumoto, S., Ohmatsu, H., Ohe, Y., & Goto, K. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.09.025 · Cited by 50 · see citing works
Up-Regulation of miR-21 Expression Predicate Advanced Clinicopathological Features and Poor Prognosis in Patients with Non-Small Cell Lung Cancer
Tian, L., Shan, W., Zhang, Y., Lv, X., Li, X., & Wei, C. (2015) · Pathology & Oncology Research · doi:10.1007/s12253-015-9979-7 · Cited by 49 · see citing works
Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations
Peng, L., Song, Z.-G., & Jiao, S.-C. (2014) · Scientific Reports · doi:10.1038/srep06104 · Cited by 48 · see citing works
Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non–small-cell Lung Cancer
Kawamura, T., Kenmotsu, H., Omori, S., Nakashima, K., Wakuda, K., Ono, A., Naito, T., Murakami, H., Omae, K., Mori, K. P., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.07.002 · Cited by 48 · see citing works
Unique genomic profiles obtained from cerebrospinal fluid cell-free DNA of non-small cell lung cancer patients with leptomeningeal metastases
Ying, S., Ke, H., Ding, Y., Liu, Y., Tang, X., Yang, D., Li, M., Liu, J., Yu, B., Xiang, J., et al. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1538614 · Cited by 47 · see citing works
EGFR T790M: revealing the secrets of a gatekeeper
Ko, B., Paucar, D., & Halmos, B. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s117944 · Cited by 47 · see citing works
Treatment options for EGFR mutant NSCLC with CNS involvement—Can patients BLOOM with the use of next generation EGFR TKIs?
Tan, C., Cho, B. C., & Soo, R. A. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.02.012 · Cited by 45 · see citing works
EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
Otsuka, K., Hata, A., Takeshita, J., Okuda, C., Kaji, R., Masago, K., Fujita, S., & Katakami, N. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2867-8 · Cited by 43 · see citing works
Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy
Xu, Y., Hu, M., Zhang, M., Zhong, W., Yin, X., Sun, Y., Chen, M., Zhao, J., Si, X., Wang, H., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.08.017 · Cited by 42 · see citing works
Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non‐small cell lung cancer
Sacher, A. G., Janne, P. A., & Oxnard, G. R. (2014) · Cancer · doi:10.1002/cncr.28723 · Cited by 41 · see citing works
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy
Ricciuti, B., Baglivo, S., Paglialunga, L., Giglio, A. D., Bellezza, G., Chiari, R., Crinò, L., & Metro, G. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017702820 · Cited by 39 · see citing works
Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation
Oya, Y., Yoshida, T., Kuroda, H., Shimizu, J., Horio, Y., Sakao, Y., Inaba, Y., Hida, T., & Yatabe, Y. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.05.004 · Cited by 38 · see citing works
Programmed death-ligand 1 expression and T790M status in EGFR -mutant non-small cell lung cancer
Hata, A., Katakami, N., Nanjo, S., Okuda, C., Kaji, R., Masago, K., Fujita, S., Yoshida, H., Zama, K., Imai, Y., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.022 · Cited by 38 · see citing works
Epidermal growth factor receptor ( EGFR ) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non‐small cell lung cancer progression during first‐generation tyrosine kinase inhibitor therapy: a prospective observational study
Zhang, S., Zhu, L., Xia, B., Chen, E., Zhao, Q., Zhang, X., Chen, X., Chen, X., & Ma, S. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0303-2 · Cited by 38 · see citing works
Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer
Takeuchi, S., Hase, T., Shimizu, S., Ando, M., Hata, A., Murakami, H., Kawakami, T., Nagase, K., Yoshimura, K., Fujiwara, T., et al. (2019) · Cancer Science · doi:10.1111/cas.14260 · Cited by 37 · see citing works
Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients
Dono, M., Luca, G. D., Lastraioli, S., Anselmi, G., Bello, M. G. D., Coco, S., Vanni, I., Grossi, F., Vigani, A., Genova, C., et al. (2019) · Molecular Medicine · doi:10.1186/s10020-019-0082-5 · Cited by 36 · see citing works
EGFR gene deregulation mechanisms in lung adenocarcinoma: A molecular review
Tsiambas, E., Lefas, A. Y., Georgiannos, S. N., Ragos, V., Fotiades, P. P., Grapsa, D., Σταματελόπουλος, Α., Kavantzas, N., Patsouris, E., & Syrigos, K. (2016) · Pathology - Research and Practice · doi:10.1016/j.prp.2016.06.005 · Cited by 34 · see citing works
AZD9291 in EGFR -Mutant Advanced Non-Small-Cell Lung Cancer Patients
Remon, J., & Planchard, D. (2015) · Future Oncology · doi:10.2217/fon.15.250 · Cited by 33 · see citing works
Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway
Ma, W., Kang, Y., Ning, L., Tan, J., Wang, H., & Yi, Y. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4847 · Cited by 33 · see citing works
ZWINT is the next potential target for lung cancer therapy
Peng, F., Li, Q., Niu, S.-Q., Shen, G.-P., Luo, Y., Chen, M., & Bao, Y. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2823-1 · Cited by 33 · see citing works
Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
Baldacci, S., Mazières, J., Tomasini, P., Girard, N., Guisier, F., Audigier-Valette, C., Monnet, I., Wislez, M., Pérol, M., Dô, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21707 · Cited by 32 · see citing works
Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial
Kim, D., Lee, K. H., Han, J., Lee, J.-S., Cho, B. C., Kang, J. H., Lee, K. H., Cho, E. K., Kim, J.-S., Min, Y. J., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.07.007 · Cited by 33 · see citing works
Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients
Alvarez-Breckenridge, C. A., Remón, J., Piña, Y., Nieblas‐Bedolla, E., Forsyth, P. A., Hendriks, L. E. L., & Brastianos, P. K. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_352320 · Cited by 32 · see citing works
Bronchoscopic Re-biopsy for Mutational Analysis of Non-small Cell Lung Cancer
Kirita, K., Izumo, T., Matsumoto, Y., Hiraishi, Y., & Tsuchida, T. (2016) · Lung · doi:10.1007/s00408-016-9864-5 · Cited by 32 · see citing works
Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients
Qian, Y., Huang, F., Zhang, M., Ji, H., Wu, S., Zhao, Y., Zhang, C., Wu, J., Wang, B., Pan, B., et al. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6712 · Cited by 31 · see citing works
Prognostic analysis and risk stratification of lung adenocarcinoma undergoing EGFR-TKI therapy with time-serial CT-based radiomics signature
Zhang, X., Lu, B., Yang, X., Lan, D., Lin, S., Zhou, Z., Li, K., Deng, D. H., Peng, P., Zeng, Z., et al. (2022) · European Radiology · doi:10.1007/s00330-022-09123-5 · Cited by 30 · see citing works
High PD-L1 Expression is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
Yoon, B. W., Chang, B., & Lee, S. H. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s271011 · Cited by 30 · see citing works
Clinical Likelihood of Sporadic Primary EGFR T790M Mutation in EGFR-Mutant Lung Cancer
Lee, Y., Lee, G. K., Hwang, J.-A., Yun, T., Kim, H. T., & Lee, J. S. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.09.002 · Cited by 28 · see citing works
The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
Tseng, J., Su, K., Yang, T., Chen, K., Hsu, K.-H., Chen, H., Tsai, C., Yu, S., & Chang, G. (2016) · Oncotarget · doi:10.18632/oncotarget.10351 · Cited by 28 · see citing works
Feasibility of re‐biopsy and EGFR mutation analysis in patients with non‐small cell lung cancer
Kim, T., Oh, I., Kho, B., Park, H. Y., Chang, J., Park, C., Shin, H., Lim, J. H., Kwon, Y. S., Kim, Y., et al. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12762 · Cited by 26 · see citing works
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy
Maso, A. D., Lorenzi, M., Roca, E., Pilotto, S., Macerelli, M., Polo, V., Cecere, F. L., Conte, A. D., Nardo, G., Buoro, V., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.07.009 · Cited by 26 · see citing works
Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study
Peled, N., Kian, W., Inbar, E., Goldstein, I. M., Zemel, M., Rotem, O., Rozenblum, A. B., Nechushtan, H., Dudnik, E., Levin, D., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab188 · Cited by 26 · see citing works
Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer
Metro, G., Chiari, R., Ricciuti, B., Rebonato, A., Lupattelli, M., Gori, S., Bennati, C., Castrioto, C., Floridi, P., Minotti, V., et al. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1094056 · Cited by 26 · see citing works
Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non–Small-Cell Lung Cancer (NSCLC)
Gaut, D. L., Sim, M., Yue, Y., Wolf, B. R., Abarca, P. A., Carroll, J., Goldman, J. W., & Garon, E. B. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.06.004 · Cited by 26 · see citing works
Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients
Dong, L., Lei, D., & Zhang, H. (2017) · Oncotarget · doi:10.18632/oncotarget.19925 · Cited by 25 · see citing works
BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation
Zhan, Y., Wang, Y., Qi, M., Liang, P., Ma, Y., Li, T., Li, H., Dai, C., An, Z., Qi, Y., et al. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0322-y · Cited by 25 · see citing works
Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
Ulivi, P. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071186 · Cited by 24 · see citing works
Dynamic monitoring of EGFR mutations in circulating cell-free DNA for EGFR-mutant metastatic patients with lung cancer: Early detection of drug resistance and prognostic significance
Ni, J., Weng, L., Liu, Y., Sun, Z., Bai, C., & Wang, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.6022 · Cited by 23 · see citing works
Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
Xiong, L., Cui, S., Ding, J., Sun, Y., Zhang, L., Zhao, Y., Gu, A., Chu, T., Wang, H., Zhong, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19139 · Cited by 23 · see citing works
Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance
Zhao, Z.-R., Wang, J., Lin, Y., Wang, F., Fu, S., Zhang, S.-L., Su, X., Jiang, L., Zhang, Y.-G., Shao, J., et al. (2013) · Medical Oncology · doi:10.1007/s12032-013-0810-6 · Cited by 23 · see citing works
A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403
Oda, N., Hotta, K., Ninomiya, K., Minami, D., Ichihara, E., Murakami, T., Yokoyama, T., Ichikawa, H., Chikamori, K., Takigawa, N., et al. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3694-5 · Cited by 24 · see citing works
Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis
Xing, P., Mu, Y., Hao, X., Wang, Y.-Q., & Li, J. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02071-5 · Cited by 24 · see citing works
Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
Corallo, S., D’Argento, E., Strippoli, A., Basso, M., Monterisi, S., Rossi, S., Cassano, A., & Barone, C. M. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0479-4 · Cited by 22 · see citing works
Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation
Barrón, F., Cardona, A. F., Corrales, L., Tirado, L. A. R., Caballé‐Perez, E., Sanchez, G., Flores‐Estrada, D., Zatarain-Barrón, Z. L., & Arrieta, O. G. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.03.106 · Cited by 21 · see citing works
Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon EGFR Mutations
Ma, C., Zhang, J., Tang, D., Ye, X., Li, J., Mu, N., Li, Z., Liu, R., Xiang, L., Huang, C., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00224 · Cited by 22 · see citing works
Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Felip, E., Concha, Á., de Castro, J., Gómez‐Román, J., Garrido, P., Ramírez, J., Isla, D., Sanz, J., Paz-Ares, L. G., & López‐Ríos, F. (2014) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1248-9 · Cited by 21 · see citing works

Rebiopsy of non-small cell lung cancer patients with acquired resistance to EGFR-TKI: Comparison between T790M mutation-positive and -negative populations.
Hata, A., Katakami, N., Yoshioka, H., Takeshita, J., Tanaka, K., Nanjo, S., Kaji, R., Fujita, S., Imai, Y., Monden, K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.7528 · Cited by 9 · see citing works
Spatiotemporal T790M heterogeneity in individual patients with non-small cell lung cancer (NSCLC) after acquired resistance to EGFR-tyrosine kinase inhibitor (TKI).
Hata, A., Katakami, N., Yoshioka, H., Masago, K., Fujita, S., Imai, Y., Tomii, K., Nishiyama, A., & Ishida, T. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8067 · Cited by 2 · see citing works
Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non–small-cell Lung Cancer
Kawamura, T., Kenmotsu, H., Omori, S., Nakashima, K., Wakuda, K., Ono, A., Naito, T., Murakami, H., Omae, K., Mori, K. P., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.07.002 · Cited by 48 · see citing works
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
Oxnard, G. R., Arcila, M. E., Sima, C. S., Riely, G. J., Chmielecki, J., Kris, M. G., Pao, W., Ladanyi, M., & Miller, V. A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2692 · Cited by 627 · see citing works
Abstract 4899: The impact of the EGFR -T790M mutation detection by re-biopsy in EGFR mutant NSCLC patients in the retrospective analysis
Yoshimura, A., Yamada, T., Okura, N., Uchino, J., & Takayama, K. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-4899

Authors: Hata, A., Katakami, N., Yoshioka, H., Takeshita, J., Tanaka, K., Nanjo, S., Fujita, S., Kaji, R., Imai, Y., Monden, K., Matsumoto, T., Nagata, K., Otsuka, K., Tachikawa, R., Tomii, K., Kunimasa, K., Iwasaku, M., Nishiyama, A., Ishida, T., & Nishimura, Y.
Affiliations: Foundation for Biomedical Research and Innovation (JP)
Kurashiki Central Hospital (JP)
Kobe City Medical Center General Hospital (JP)
Kobe University (JP)
Corresponding author: Hata, Akito
ORCID: Hata, Akito
Katakami, Nobuyuki
Yoshioka, Hiroshige
Tanaka, Kosuke
Nanjo, Shigeki
Fujita, Shiro
Imai, Yukihiro
Monden, Kazuya
Matsumoto, Takeshi
Nagata, Kazuma
Tomii, Keisuke
Kunimasa, Kei
Iwasaku, Masahiro
Nishiyama, Akihiro
Ishida, Tadashi
Nishimura, Yoshihiro
Venue: Cancer
Publisher: Wiley
Published: 2013-09-16
Volume: 119
Issue: 24
Pages: 4325-4332
ISSN: 0008-543X (ISSN-L)
1097-0142
DOI: 10.1002/cncr.28364
OpenAlex: W1607191560
Cited by: 178
References: 37
Citations by year: 2025: 3 · 2024: 6 · 2023: 3 · 2022: 13 · 2021: 6 · 2020: 6 · 2019: 19 · 2018: 30 · 2017: 33 · 2016: 27 · 2015: 15 · 2014: 15 · 2013: 2
FWCI: 15.98
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Cancer (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: non-small cell lung cancer, EGFR tyrosine kinase inhibitors, acquired drug resistance, T790M mutation, repeat biopsy, central nervous system lesions, prognostic factors, post-progression survival, leptomeningeal metastasis, EGFR mutation testing
MeSH terms: Aged, Antineoplastic Agents, Biopsy, Carcinoma, Non-Small-Cell Lung, DNA Mutational Analysis, Female, Humans, Lung Neoplasms, Male, Mutation, Protein-Tyrosine Kinases, Retrospective Studies, Disease Progression, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: Comparison between T790M mutation‐positive and mutation‐negative populations

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks